For the year ending 2025-12-31, UPB had -$224,314K decrease in cash & cash equivalents over the period. -$133,440K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -143,443 |
| Depreciation and amortization expense | 188 |
| Stock-based compensation expense | 10,332 |
| Change in fair value of preferred stock tranche right liability | 0 |
| Net amortization of premiums and accretion of discounts on short-term investments | 1,502 |
| Non-cash lease expense | 561 |
| Accounts receivable | 55 |
| Prepaid expenses and other assets | 1,524 |
| Accounts payable | -1,281 |
| Accrued expenses and other current liabilities | 4,014 |
| Operating lease liabilities | -565 |
| Net cash used in operating activities | -133,275 |
| Purchases of short-term investments | 385,878 |
| Maturities of short-term investments | 292,563 |
| Purchases of equipment | 165 |
| Net cash used in investing activities | -93,480 |
| Proceeds from the issuance of series b redeemable convertible preferred stock, net of issuance costs paid | 0 |
| Proceeds from initial public offering, net of underwriters discounts and commissions | 0 |
| Payments of initial public offering costs | 34 |
| Proceeds from exercises of stock options | 2,279 |
| Proceeds from issuance of common stock under employee stock purchase plan | 196 |
| Net cash provided by financing activities | 2,441 |
| Net increase (decrease) in cash, cash equivalents and restricted cash | -224,314 |
| Cash, cash equivalents and restricted cash at beginning of period | 326,086 |
| Cash, cash equivalents and restricted cash at end of period | 101,772 |
Upstream Bio, Inc. (UPB)
Upstream Bio, Inc. (UPB)